Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)
China · Delayed Price · Currency is CNY 10.94
+0.19 (1.77%)
Oct 23, 2026, 3:04 PM CST
SHE:301211 Revenue
Hubei Biocause Heilen Pharmaceutical had revenue of 127.35M CNY in the quarter ending June 30, 2026, with 5.84% growth. This brings the company's total for the last twelve months to 466.05M, up 6.22% year-over-year. In the year 2025, Hubei Biocause Heilen Pharmaceutical had annual revenue of 453.31M with 1.67% growth. That makes Hubei Biocause Heilen Pharmaceutical the 25,437th largest company in the world by revenue and 4,524th in China.
Revenue (ttm)
466.05M
Revenue Growth
+6.22%
P/S Ratio
9.80
Revenue / Employee
489.55K
Employees
952
Market Cap
4.57B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHE:301211 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 453.31M | 7.44M | 1.67% |
| Dec 31, 2024 | 445.86M | -217.16M | -32.75% |
| Dec 31, 2023 | 663.03M | 148.11M | 28.76% |
| Jan 1, 2023 | 514.91M | -25.71M | -4.76% |
| Jan 1, 2022 | 540.62M | -52.30M | -8.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.